Related references
Note: Only part of the references are listed.Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI
Alain M. Schoepfer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
This Month in Gastroenterology
Jan Tack et al.
GASTROENTEROLOGY (2010)
Tailoring the length of antiviral treatment for hepatitis C
Alessandra Mangia et al.
GUT (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment
Taina Sipponen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2010)
Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis
Patrick F. van Rheenen et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
A fat chance for hepatocyte transplantation?
James A. Thomas et al.
GUT (2009)
Endpoints for Clinical Trials Evaluating Disease Modification and Structural Damage in Adults with Crohn's Disease
Geert R. D'Haens et al.
INFLAMMATORY BOWEL DISEASES (2009)
Ulcerative Colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with Fecal Calprotectin, Clinical Activity, C-reactive Protein, and Blood Leukocytes
Alain M. Schoepfer et al.
INFLAMMATORY BOWEL DISEASES (2009)
Fecal Calprotectin, Lactoferrin, and Endoscopic Disease Activity in Monitoring Anti-TNF-alpha Therapy for Crohn's Disease
Taina Sipponen et al.
INFLAMMATORY BOWEL DISEASES (2008)
Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease
Renata D'Inca et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease
F Costa et al.
GUT (2005)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
M Rutter et al.
GASTROENTEROLOGY (2004)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease
AG Roseth et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2004)
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children
A Carroccio et al.
CLINICAL CHEMISTRY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
A review of activity indices and efficacy Endpoints for clinical trials of medical therapy in adults with Crohn's disease
WJ Sandborn et al.
GASTROENTEROLOGY (2002)
Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease
SK Bunn et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2001)
Share Paper
